

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
--------	-------	---	--------	------------------

**Set 1****(560) ANA screening (cell nucleus) - prove**

A1	(1) Fluorescent methods	>>>	71 Positive	91 %
	(2) EIA methods	>>>	7 Positive	9,0 %
Total per sample: n = 78		Success: 100 %		
B1	(1) Fluorescent methods	>>>	71 Negative	91 %
	(2) EIA methods	>>>	6 Negative	7,7 %
			1 Positive	1,3 %
Total per sample: n = 78		Success: 99 %		
Total success: 99 %				

**(572) ANA screening (cell nucleus) - semi-quantity**

A1	(0) Not specified	±	2 titre 40	3,0 %
		±	2 titre 320	3,0 %
		±	12 titre 640	18 %
		±	30 titre 1280	45 %
		±	21 titre 2560	31 %
Total per sample: n = 67		Success (only evaluated results): evaluation		
B1	(0) Not specified	±	1 Not specified	1,5 %
		±	47 titre 0 (not measurable)	70 %
		±	16 titre 40	24 %
		±	3 titre 80	4,5 %
Total per sample: n = 67		Success (only evaluated results): evaluation		

**(561) ANA - type of fluorescence - nucleus**

A1	(0) Not specified	>>>	65 Coarse or fine speckled	93 %
			3 Coarse or fine speckled; Nuclear matrix	4,3 %
			2 Nuclear matrix	2,9 %
Total per sample: n = 70		Success: 93 %		
B1	(0) Not specified	>>>	69 No fluorescence	99 %
			1 Coarse or fine speckled	1,4 %
Total per sample: n = 70		Success: 99 %		
Total success: 91 %				

**(563) ANA screening (cytoplasm) - prove**

A1	(1) Fluorescent methods	>>>	60 Negative	87 %
		>	1 Inconclusive result (borderline)	1,4 %
		>	8 Positive	12 %
Total per sample: n = 69		Success: 100 %		
B1	(1) Fluorescent methods	>>>	69 Negative	100 %
Total per sample: n = 69		Success: 100 %		
Total success: 100 %				

**(573) ANA screening (cytoplasm) - semi-quantity**

A1	(0) Not specified	±	36 titre 0 (not measurable)	59 %
		±	16 titre 40	26 %
		±	4 titre 80	6,6 %
		±	3 titre 160	4,9 %
		±	1 titre 320	1,6 %
		±	1 titre 640	1,6 %
Total per sample: n = 61		Success (only evaluated results): evaluation		
B1	(0) Not specified	±	43 titre 0 (not measurable)	70 %
		±	15 titre 40	25 %
		±	3 titre 80	4,9 %
Total per sample: n = 61		Success (only evaluated results): evaluation		

**(564) ANA - type of fluorescence - cytoplasm**

A1	(0) Not specified	>>>	59 No fluorescence	87 %
		>	5 Fine speckled cytoplasmic pattern	7,4 %
		>	4 Diffusion cytoplasmic picture	5,9 %
Total per sample: n = 68		Success: 100 %		
B1	(0) Not specified	>>>	68 No fluorescence	100 %
Total per sample: n = 68		Success: 100 %		
Total success: 100 %				

Test		N	Result	N <sub>rel</sub>
Sample	Group			
<b>Set 2</b>				
<b>(565) ANCA immunofluorescence - prove</b>				
A2	(1) Fluorescent met. (ethanol)	>>> 49	Positive	75 %
	(2) Fluorescent met. (formalin)	>>> 6	Positive	9,2 %
	(99) Another measurement principle	>>> 10	Positive	15 %
----- Total per sample: n = 65 -----		Success: 100 %		
B2	(1) Fluorescent met. (ethanol)	1	Negative	1,5 %
		1	Inconclusive result (borderline)	1,5 %
		>>> 47	Positive	72 %
	(2) Fluorescent met. (formalin)	>>> 6	Positive	9,2 %
	(99) Another measurement principle	>>> 10	Positive	15 %
----- Total per sample: n = 65 -----		Success: 97 %		
Total success: 97 %				
<b>(574) ANCA IF (ethanol) - semi-quantity</b>				
A2	(0) Not specified	± 5	titre 20	9,4 %
		± 3	titre 40	5,7 %
		± 12	titre 80	23 %
		± 12	titre 160	23 %
		± 9	titre 320	17 %
		± 9	titre 640	17 %
		± 1	titre 1280	1,9 %
		± 2	titre 2560	3,8 %
----- Total per sample: n = 53 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 5	titre 20	9,4 %
		± 2	titre 40	3,8 %
		± 7	titre 80	13 %
		± 17	titre 160	32 %
		± 14	titre 320	26 %
		± 6	titre 640	11 %
		± 2	titre 1280	3,8 %
----- Total per sample: n = 53 -----		Success (only evaluated results):	evaluation	
<b>(578) ANCA IF (formalin) - semi-quantity</b>				
A2	(0) Not specified	± 4	titre 20	8,0 %
		± 6	titre 40	12 %
		± 7	titre 80	14 %
		± 17	titre 160	34 %
		± 9	titre 320	18 %
		± 4	titre 640	8,0 %
		± 1	titre 1280	2,0 %
		± 2	titre 2560	4,0 %
----- Total per sample: n = 50 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 3	titre 20	6,0 %
		± 4	titre 80	8,0 %
		± 16	titre 160	32 %
		± 19	titre 320	38 %
		± 7	titre 640	14 %
		± 1	titre 1280	2,0 %
----- Total per sample: n = 50 -----		Success (only evaluated results):	evaluation	
<b>(566) ANCA - type of fluorescence</b>				
A2	(0) Not specified	>>> 50	Perinuclear fluorescence	81 %
		>>> 11	Perinuclear fluorescence; ANA	18 %
		1	ANA	1,6 %
----- Total per sample: n = 62 -----		Success: 98 %		
B2	(0) Not specified	1	No fluorescence	1,6 %
		2	Perinuclear fluorescence	3,2 %
		>>> 59	Cytoplasmic granular fluorescence	95 %
----- Total per sample: n = 62 -----		Success: 95 %		
Total success: 94 %				
<b>(569) anti-myeloperoxidase</b>				
A2	(1) Fluorescent methods	>>> 2	Positive	2,8 %
	(2) EIA methods	1	Negative	1,4 %
		>>> 49	Positive	68 %
	(5) LIA, ILMA	>>> 9	Positive	13 %
	(6) Immunoblotting	>>> 10	Positive	14 %
	(99) Another measurement principle	>>> 1	Positive	1,4 %
----- Total per sample: n = 72 -----		Success: 99 %		
B2	(1) Fluorescent methods	>>> 2	Negative	2,8 %
	(2) EIA methods	>>> 49	Negative	68 %
		1	Positive	1,4 %

## EQA round: AIM2/21 - Autoimmunity

Test			N	Result	N <sub>rel</sub>
Sample	Group				
B2	(5) LIA, ILMA	>>>	9	Negative	13 %
	(6) Immunoblotting	>>>	10	Negative	14 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
	Total per sample: n = 72		Success: 99 %		
Total success: 99 %					
<b>(570) anti-proteinase III</b>					
A2	(1) Fluorescent methods	>>>	2	Negative	2,8 %
	(2) EIA methods	>>>	49	Negative	68 %
				1	Positive
	(5) LIA, ILMA	>>>	9	Negative	13 %
	(6) Immunoblotting	>>>	10	Negative	14 %
(99) Another measurement principle	>>>	1	Negative	1,4 %	
Total per sample: n = 72		Success: 99 %			
B2	(1) Fluorescent methods	>>>	2	Positive	2,8 %
	(2) EIA methods	>>>	2	Negative	2,8 %
			>>>	48	Positive
	(5) LIA, ILMA	>>>	9	Positive	13 %
	(6) Immunoblotting	>>>	1	Negative	1,4 %
	(99) Another measurement principle	>>>	9	Positive	13 %
Total per sample: n = 72		Success: 96 %			
Total success: 96 %					
<b>Set 3</b>					
<b>(580) Anti-ENA/SS-A/Ro-60</b>					
A3	(2) EIA methods	>>>	29	Positive	38 %
	(5) LIA, ILMA	>>>	3	Positive	3,9 %
	(6) Immunoblotting	>>>	43	Positive	56 %
	(99) Another measurement principle	>>>	2	Positive	2,6 %
Total per sample: n = 77		Success: 100 %			
B3	(2) EIA methods	>>>	28	Negative	36 %
			1	Positive	1,3 %
	(5) LIA, ILMA	>>>	2	Negative	2,6 %
			1	Positive	1,3 %
	(6) Immunoblotting		1	Not specified	1,3 %
		>>>	40	Negative	52 %
(99) Another measurement principle	>>>	2	Positive	2,6 %	
Total per sample: n = 77		Success: 94 %			
Total success: 94 %					
<b>(581) Anti-ENA/SS-B/La</b>					
A3	(2) EIA methods	>>>	29	Positive	38 %
	(5) LIA, ILMA	>>>	3	Positive	3,9 %
	(6) Immunoblotting	>>>	43	Positive	56 %
	(99) Another measurement principle	>>>	2	Positive	2,6 %
Total per sample: n = 77		Success: 100 %			
B3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	3,9 %
	(6) Immunoblotting		1	Not specified	1,3 %
		>>>	41	Negative	53 %
	(99) Another measurement principle	>>>	1	Positive	1,3 %
(99) Another measurement principle	>>>	2	Negative	2,6 %	
Total per sample: n = 77		Success: 97 %			
Total success: 97 %					
<b>(582) Anti-ENA/Scl-70</b>					
A3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	3,9 %
	(6) Immunoblotting	>>>	43	Negative	56 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77		Success: 100 %			
B3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	3,9 %
	(6) Immunoblotting		1	Not specified	1,3 %
		>>>	42	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77		Success: 99 %			
Total success: 99 %					

Test	Sample	Group	N	Result	N <sub>rel</sub>
<b>(583) Anti-ENA/RNP</b>					
A3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	4	Negative	5,2 %
	(6) Immunoblotting	>>>	42	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77			Success: 100 %		
B3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	4	Negative	5,2 %
	(6) Immunoblotting	>>>	1	Not specified	1,3 %
	(99) Another measurement principle	>>>	41	Negative	53 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77			Success: 99 %		
Total success: 99 %					
<b>(584) Anti-ENA/Jo-1</b>					
A3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	4	Negative	5,2 %
	(6) Immunoblotting	>>>	42	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77			Success: 100 %		
B3	(2) EIA methods	>>>	29	Negative	38 %
	(5) LIA, ILMA	>>>	4	Negative	5,2 %
	(6) Immunoblotting	>>>	1	Not specified	1,3 %
	(99) Another measurement principle	>>>	41	Negative	53 %
	(99) Another measurement principle	>>>	2	Negative	2,6 %
Total per sample: n = 77			Success: 99 %		
Total success: 99 %					
<b>(585) Anti-centromere antibodies</b>					
A3	(1) Fluorescent methods	>>>	8	Negative	11 %
	(2) EIA methods	>>>	17	Negative	24 %
	(5) LIA, ILMA	>>>	2	Negative	2,8 %
	(6) Immunoblotting	>>>	43	Negative	61 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71			Success: 100 %		
B3	(1) Fluorescent methods	>>>	8	Negative	11 %
	(2) EIA methods	>>>	17	Negative	24 %
	(5) LIA, ILMA	>>>	2	Negative	2,8 %
	(6) Immunoblotting	>>>	1	Not specified	1,4 %
	(99) Another measurement principle	>>>	42	Negative	59 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71			Success: 99 %		
Total success: 99 %					
<b>Set 4</b>					
<b>(588) Anti-ds-DNA immunofluores. - prove</b>					
A4	(0) Not specified	>>>	57	Positive	100 %
Total per sample: n = 57			Success: 100 %		
B4	(0) Not specified	>>>	1	Not specified	1,8 %
	(99) Another measurement principle	>>>	56	Negative	98 %
Total per sample: n = 57			Success: 98 %		
Total success: 98 %					
<b>(577) Anti-ds-DNA immunofluor. - semi-quantity</b>					
A4	(0) Not specified	±	2	titre 10	3,8 %
		±	1	titre 40	1,9 %
		±	15	titre 80	28 %
		±	16	titre 160	30 %
		±	10	titre 320	19 %
		±	8	titre 640	15 %
		±	1	titre 1280	1,9 %
Total per sample: n = 53			Success (only evaluated results):	evaluation	
B4	(0) Not specified	±	1	Not specified	1,9 %
		±	38	titre 0 (not measurable)	72 %
		±	14	titre 10	26 %
Total per sample: n = 53			Success (only evaluated results):	evaluation	
<b>(589) Anti-ds-DNA other methods</b>					
A4	(2) EIA methods	>>>	45	Positive	80 %
	(5) LIA, ILMA	>>>	5	Positive	8,9 %
	(6) Immunoblotting	>>>	5	Positive	8,9 %
	(99) Another measurement principle	>>>	1	Positive	1,8 %

## Summary statistics - qualitative results

(Groups: measurement principle)

## EQA round: AIM2/21 - Autoimmunity

Deadline: 04.10.2021

## Test

Sample	Group	N	Result	N <sub>rel</sub>
Total per sample: n = 56		Success: 100 %		
B4	(2) EIA methods	>>> 45	Negative	80 %
	(5) LIA, ILMA	>>> 5	Negative	8,9 %
	(6) Immunoblotting	>>> 5	Negative	8,9 %
	(99) Another measurement principle	>>> 1	Negative	1,8 %
Total per sample: n = 56		Success: 100 %		
Total success: 100 %				

## Set 5

## (591) Anti-nucleosomes IgG

A5	(2) EIA methods	1	Negative	1,8 %
		>>> 38	Positive	69 %
	(6) Immunoblotting	>>> 16	Positive	29 %
Total per sample: n = 55		Success: 98 %		
B5	(2) EIA methods	>>> 39	Negative	71 %
	(6) Immunoblotting	>>> 16	Negative	29 %
Total per sample: n = 55		Success: 100 %		
Total success: 98 %				

st\_kl

End of report

Printed: 12.10.2021